Dr. Crinò on Crizotinib in ALK-Positive NSCLC
Lucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer
Lucio Crinò, MD, Director, Department of Oncology, University Hospital of Perugia, Italy, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer (NSCLC).
In this phase III trial, Crinò says, crizotinib showed superior activity compared with chemotherapy in patients with ALK+ NSCLC. Crizotinib showed a response rate of 65-70% compared to standard therapy, which only showed a response rate of about 10-28%, Crinò says.
There was also a significant improvement in progression-free survival. While standard treatments such as chemotherapy only show a progression-free survival rate of 3.5 months, Crinò says, there is a progression-free survival rate approaching 8 or 9 months with crizotinib.
<<<
